The FoxP3 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population targeting the FOXP3 gene in the human Raji B lymphocyte line. This product provides a functionally heterogeneous pool of gene-edited cells, enabling robust loss-of-function studies without single-cell cloning, preserving the natural variability required for high-throughput phenotypic screening and population-based assays.
Raji cells are a suspension-adapted B lymphocyte line isolated from a Burkitt lymphoma patient and are positive for Epstein-Barr virus (EBV). They serve as a well-established model for B cell signaling, lymphoma biology, and virology, offering a platform to study malignant transformation and immune cell interactions. In wild-type Raji cells, FOXP3 expression is low, making the knockout particularly useful for assessing gain-of-function complements or uncovering cryptic regulatory roles in B cell physiology.
FOXP3, a forkhead box transcription factor, is the master regulator of regulatory T cell (Treg) identity and function. Its activation is driven by TCR stimulation, IL-2/STAT5, and TGF-??/SMAD pathways, acting through transcriptional complexes containing NFAT, NF-??B, AML1/Runx1, and IRF4. FOXP3 directly represses pro-inflammatory cytokines such as IL-2 while activating immunosuppressive molecules like CTLA-4, CD25, IL-10, TGF-??, and CD39, thus maintaining immune homeostasis. The key TCR?CIL-2R?CSTAT5?CSMAD3?CFOXP3?CCTLA-4 axis underscores its central role in Treg differentiation and self-tolerance.
Although FOXP3 is predominantly studied in Tregs, its potential functions in B lymphocytes remain largely unexplored. The Raji FOXP3 knockout polyclonal population allows for interrogation of FOXP3??s role in B cell lymphoma, including its impact on NF-??B signaling, apoptosis resistance, and interactions with EBV oncoproteins. This model can be used to test whether FOXP3 acts as a molecular brake on B cell proliferation or contributes to immune evasion, offering a novel tool for lymphoma research and drug discovery.
Detailed research applications encompass transcriptomic profiling by RNA-seq to identify FOXP3-dependent gene networks, quantitative RT-qPCR and western blot validation of targets like CTLA-4 and IL-10, and flow cytometry for assessing surface markers CD25 and CTLA-4 in a B cell context. Functional assays, including luciferase-based FOXP3 reporter screening of small-molecule libraries, proliferation and apoptosis analyses, and co-culture systems with T cells, can further elucidate immunoregulatory mechanisms. For additional information or tailored applications, please contact Ascent Research.
